Q-omics provides the consensus-scored RBAKDN profile across patient tissues and cancer cell-line models. RBAKDN expression is associated with patient survival in 26 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, RBAKDN is differentially expressed in 10, with the highest sampling consensus in HNSC. Additionally, RBAKDN RNA expression shows 8,161 significant gene co-expression associations, with the highest sampling consensus in TGCT. Together, these results highlight KIRC, HNSC, and TGCT as cancer lineages where RBAKDN shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for RBAKDN — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes RBAKDN survival associations across molecular data types. RBAKDN RNA expression shows survival associations in the most cancer types (26). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible RBAKDN RNA expression–survival associations across cancer types. High RBAKDN expression shows unfavorable associations in KIRC, UVM, ACC, OV, CESC and COAD. The KIRC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for RBAKDN RNA expression.
This table summarizes RBAKDN tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 10. The strongest signals are observed in HNSC for RNA.
This table ranks reproducible tumor–normal expression differences for RBAKDN. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. RBAKDN shows higher tumor expression in HNSC, COAD, BRCA, LUSC, UCEC and BLCA. The HNSC box plot shows higher RBAKDN RNA expression in tumor versus normal tissue (log2 FC = +0.539, t-test p < 0.001).
This table shows molecular features associated with RBAKDN in patient tissues and cancer cell lines. In patient samples, RBAKDN shows the broadest associations at the RNA and protein expression levels, with TGCT recurring as the lineage with the largest associated feature set.
